Nicholas Deptula, PA
Medical · Richmond, VANPI 1942558036
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Phathom Pharmaceuticals, Inc. accounts for 62.7% of it on its own, with 27 other manufacturers making up the rest. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $36.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$11K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$611
- Johnson & Johnson$362
- Ardelyx, Inc.$351
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$5,18031%
- Travel & lodging$3,95423%
- Food & beverage$7,75846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 87 | $10,583 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 93 | $1,233 |
| AbbVie | 79 | $1,080 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $611 |
| Johnson & Johnson | 19 | $362 |
| Ardelyx, Inc. | 19 | $351 |
| Gilead | 14 | $316 |
| Sanofi | 13 | $310 |
| Regeneron Healthcare Solutions, Inc. | 13 | $285 |
| Novo Nordisk | 3 | $268 |
| Ipsen Biopharmaceuticals, Inc | 7 | $268 |
| Bristol Myers Squibb | 12 | $206 |
| Pfizer | 11 | $191 |
| Nestle Healthcare Nutrition Inc. | 7 | $132 |
| Intercept Pharmaceuticals, Inc. | 7 | $104 |
| Ironwood Pharmaceuticals, Inc | 6 | $102 |
| Madrigal Pharmaceuticals | 3 | $75 |
| Lilly USA, LLC | 3 | $71 |
| Merck | 3 | $59 |
| QOL Medical, LLC | 2 | $59 |
| Redhill Biopharma Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Evoke Pharma, Inc. | 2 | $29 |
| Braintree Laboratories, Inc. | 2 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Sandoz | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Medtronic | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,892 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 16 | $133,713 |
| XifaxanRifaximin | 30 | $74,041 |
| LinzessLinaclotide | 37 | $39,633 |
| TrulancePlecanatide | 22 | $25,800 |
| MotegrityPrucalopride Succinate | 21 | $22,801 |
| VoqueznaVonoprazan Fumarate | 12 | $9,877 |
| MovantikNaloxegol Oxalate | 18 | $8,028 |
| Mesalamine | 20 | $4,452 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,910 |
| Lubiprostone | 47 | $3,672 |
| Omeprazole | 177 | $2,026 |
| Rabeprazole Sodium | 61 | $1,722 |
| Budesonide DrBudesonide | 15 | $1,688 |
| Ondansetron OdtOndansetron | 21 | $1,666 |
| Dicyclomine Hcl | 56 | $1,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $25 | $133,71316 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,233 | $99,84052 claims |
| AbbVieLinzess | $1,080 | $39,63337 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $611 | $22,80121 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $10,583 | $9,87712 claims |
| Redhill Biopharma Inc.Movantik | $35 | $8,02818 claims |
| SandozLansoprazole | $27 | $1,07435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Richmond
- Sara VillalonaRichmond$240K
- Janlyn AnthonyRichmond$18K
- Lori WoodRichmond$13K
- Emily RevensonRichmond$12K
- Thomas CawleyRichmond$8K
- Aesha ParikhRichmond$8K
- Jenny AmbrosinoRichmond$7K
- Michele RhoeRichmond$6K
- Elizabeth RhamyRichmond$6K
- Bryan UrquhartFredericksburg$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.